Clinical Trial

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, phase 2, open label study to evaluate safety, tolerability and efficacy of SHR2554 combined with other anti-tumor treatments in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-29; most recent amendment 2025-09-09.
Status change: Not Yet Recruiting → Recruiting 2025-08-26
Trial Details
NCT Number NCT07102901
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Enrollment 351 participants
Start Date 2025-09-05
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-10